|
Press Releases |
|
![](/images/company/nanobiotix.jpg) |
|
Friday, October 21, 2016 |
|
Nanobiotix's Partner, PharmaEngine, Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia |
NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October. more info >> |
|
Tuesday, October 4, 2016 |
|
Nanobiotix Strengthens U.S. Leadership with Appointments of Head of U.S. Clinical Development and Director of Investor Relations |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced that it has strengthened its U.S. leadership team with the appointments of Dr. Mihail Obrocea as the Head of U.S. Clinical Development and Noel Kurdi as the Director of Investor Relations. more info >> |
|
Tuesday, September 20, 2016 |
|
Bpifrance Grants Nanobiotix a 2M EUR Interest-free Loan to Support Final Development Stage of Lead Product, NBTXR3 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that Bpifrance has awarded the Company an interest-free loan of EUR 2M for Innovation (pret a taux zero pour l'Innovation - PTZI). more info >> |
|
Wednesday, September 14, 2016 |
|
Nanobiotix Announces Submission for First Market Approval of Lead Product NBTXR3 in Europe |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has filed for market approval (CE Marking) in Europe for its lead product, a first-in-class radio-enhancer, NBTXR3. more info >> |
|
Thursday, July 7, 2016 |
|
Nanobiotix Reports Successful Results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer |
NANOBIOTIX, a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, today announced positive results from a Phase I/II clinical trial of its lead product, NBTXR3, for the treatment of locally advanced cancers of the oral cavity, tongue or oropharynx (head and neck cancer, or H&N) in frail and elderly patients. more info >> |
|
Tuesday, May 31, 2016 |
|
Nanobiotix Establishes Promising Preclinical Proof-of-Concept in Immuno Oncology |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that the Company has established preliminary preclinical proof-of-concept (POC) with the lead product NBTXR3 for its new program in Immuno Oncology (IO). more info >> |
|
Friday, April 29, 2016 |
|
Nanobiotix: 2015 Annual Results |
Nanobiotix (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces its audited consolidated results for the fiscal year ended December 31, 2015. more info >> |
|
Tuesday, January 5, 2016 |
|
Nanobiotix Starts a New Research Program, in Immuno Oncology, with Its Lead Product NBTXR3 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that, in addition to its current advanced clinical development program, the Company has started exploring the use of NBTXR3 for combination in Immuno Oncology. more info >> |
|
Thursday, July 2, 2015 |
|
Nanobiotix starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3 |
Nanobiotix (Euronext: NANO), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has been authorized to begin a new clinical trial in liver cancers for its lead NanoXray product, NBTXR3. more info >> |
|
Wednesday, June 10, 2015 |
|
Nanobiotix Reports Positive Preliminary Results in Head and Neck Cancer Phase I/II Clinical Trial with NBTXR3 |
NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces positive preliminary safety results for its lead NanoXray product NBTXR3, in its head and neck cancer Phase I/II clinical trial. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Best BLUETTI Prime Day Deals on Portable Power Stations and Solar Generators
Jul 16, 2024 22:00 HKT/SGT
|
|
|
Lexaria Preparing For Strategic Growth
Jul 16, 2024 21:20 HKT/SGT
|
|
|
'Alamein Festival' Launches Exciting Second Edition for 2024
Jul 16, 2024 21:00 HKT/SGT
|
|
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating
Jul 16, 2024 21:00: JST
|
|
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating
Jul 16, 2024 20:00 HKT/SGT
|
|
|
How Artificial Intelligence Can Help Give Your Business a Boost
Jul 16, 2024 19:30 HKT/SGT
|
|
|
U.S. Polo Assn. Proudly Partners with the 2024 Outsourcing Inc. Royal Charity Polo Cup
Jul 16, 2024 19:00 HKT/SGT
|
|
|
Neste and Mitsubishi Corporation agree on strategic partnership to develop supply chains for renewable chemicals and plastics
Jul 16, 2024 18:36 JST
|
|
|
NEC technology reliably measures sea levels from a greater distance
Jul 16, 2024 17:45 JST
|
|
|
全球发展数字经济直播访谈会正式举办 外方来华参会高级别代表走进东方甄选直播间
Jul 16, 2024 15:08 HKT/SGT
|
|
|
巨星傳奇(6683.HK)解禁後首個交易日 收盤報10.4港元 升幅達2.97%
Jul 16, 2024 15:04 HKT/SGT
|
|
|
巨星传奇(6683.HK)解禁后首个交易日: 收盘报10.4港元 升幅达2.97%
Jul 16, 2024 14:58 HKT/SGT
|
|
|
全球發展數字經濟直播訪談會正式舉辦 外方來華參會高級別代表走進東方甄選直播間
Jul 16, 2024 14:25 HKT/SGT
|
|
|
Fujitsu and Cohere launch strategic partnership and joint development to provide generative AI for enterprises
Jul 16, 2024 15:13 JST
|
|
|
Komisi Penerbangan Malaysia Memilih TransNusa Sebagai Salah Satu Dari Dua Maskapai Asing Untuk Meluncurkan Penerbangan Dari Bandara Subang
Jul 16, 2024 14:00 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|